USA flag logo/image

An Official Website of the United States Government

Nanocarrier formulated enzyme for the treatment of S. aureus infection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AI098130
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
PHARMAIN CORPORATION
19805 N. Creek Pkwy, Suite 200 Bothell, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Nanocarrier formulated enzyme for the treatment of S. aureus infection
Agency: HHS
Contract: 1R43AI098130-01A1
Award Amount: $600,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Lyso, a metalloendopeptidase that is bacteriolytic for S. aureus, is a potential systemic therapy for treating methicillin-resistant S. aureus (MRSA) mediated infections including endocarditis, osteomyelitis, catheter related infections, and MRSA-mediated community acquired furunculosis and pneumonia. However, the short half-life of this enzyme in vivo has precluded its development thus far as a systemic therapy, despite positive clinical trial data. Our company, PharmaIN, has developed a nanocarrier, Protected Graft Copolymers (PGC), that can reversibly bind peptides and/or proteins (US patent #7,138,105) with measurable dissociation constant (Kd). Importantly, because of its size, PGC nanocarrier concentrates at sites of increased vascular permeability and thus can potentially concentrate lyso at the site of infection. Our goal is to develop a formulation of lyso to provide life-saving treatment against MRSA and to suppress the emergence of resistance. Our preliminary data demonstrates that PGC can reversibly associate with lyso, increase blood half-life 14-fold, and increase its in vivo efficacy against MRSA by 100-fold. We propose to prepare endotoxin- free lyso and create a master cell-line bank (E. coli expressing lyso) that will be used for: 1) this project to supply our lyso needs, and 2) as reference cells for the planned post-SBIR IND filing and clinical trial. We will also optimize the structure of PGC by synthesizing variations (at least 10) of the effectivePGC shown in the preliminary data with the intention to further extend the half-life to at least 30 fold. This is important before we put a lot of resource towards IND. To this end, we will continue the development of PGC-lyso formulation by doing bindingstudies of at least 10 new carrier variations. We will do PKs and biodistribution studies on at least 6 selected lyso formulations. We will determine and compare with commercially available antibiotics the effectiveness of our lyso formulation in vivo against MRSA. PharmaIN Corp. Confidential PUBLIC HEALTH RELEVANCE: We will develop a formulation of lysostaphin (lyso) to provide a life-saving treatment against MRSA and to suppress the emergence of resistance. To this end, we will optimize the structure of PGC to extend lyso blood residence time by 30 fold and effectiveness in vivo against MRSA by more than 100-fold. We also propose to prepare endotoxin-free lyso and create a master cell-line bank (E. coli expressing lyso) that will be used for:1) this project to supply our lyso needs, and 2) as reference cells for the planned post-SBIR IND filing and clinical trial. PharmaIN Corp. Confidential

Principal Investigator:

Gerardo M. Castillo
206-568-1499
gcastillo@pharmain.com

Business Contact:

Melissa Kilcup
206-451-7105
gms@pharmain.com
Small Business Information at Submission:

PHARMAIN CORPORATION
19805 N. Creek Pkwy, Suite 200 Bothell, WA -

EIN/Tax ID: 136435786
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No